文拉法辛缓释片合并阿立哌唑治疗36例躯体化障碍对照观察

目的:探讨文拉法辛缓释片合并阿立哌唑治疗躯体化障碍的疗效及安全性。方法:将符合CCMD-3中躯体化障碍诊断标准的72例患者随机分成治疗组(n=36)和对照组(n=36),治疗组给予文拉法辛缓释片合并阿立哌唑治疗,对照组单用文拉法辛缓释片治疗。用汉密尔顿抑郁量表(HAMD),汉密尔顿焦虑量表(HAMA)及不良反应量表(TESS)评定疗效及不良反应,疗程8周。结果:在治疗2、4、6、8周末HAMD、HAMA减分率均低于对照组,两组疗效比较具有显著性统计学意义(P<0.05),两组治疗6、8周末TESS评分明显低于治疗2周末(P﹤0.01或0.01)。结论:文拉法辛缓释片合并阿立哌唑治疗躯体化障碍效果优于单用文拉法辛缓释片,且依从性好。

Venlafaxine extended release tablets combined with Aripiprazole in treatment of somatization disorder control observation

Objective:To study the Venlafaxine 53:25 o merger review body was made of the obstacles for safety and efficacy.Methods:To meet(CCMD-3) diagnosis standard of 72 cases of patients were randomly divided into the body obstacles treatment group(n = 36) and the control group(n=36),the treatment group giving Venlafaxine 53:25 o was made with Aripiprazole treatment group with Venlafaxine 53:25 treatment.With Hamilton depression rating scale(HAMD),Hamilton anxiety scale(HAMA) and side effects scale(TESS) group,the efficacy and adverse reaction in the treatment of eight weeks.Results: In the treatment of 2,4,6,8 weekend HAMD,HAMA deducted rate is lower than those of the control group,the curative effect of two more significant statistically significant(P<0.05),two groups of treatment for 6,8 weekend TESS score was significantly lower than the 2 weekend treatment(P﹤0.01 or 0.01).Conclusions: The Venlafaxine 53:25 o merger review body was made the treatment effect is better than those obstacles Venlafaxine 53:25,and compliance.